MTNB
Matinas BioPharma Holdings, Inc.
NYSE AmericanUSDEQUITY
Healthcare
DELAYED
Strong buy
+77/100
Last price
2.93
▲ 0.11 (3.90%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.86
Prev close
2.82
Day high
3.15
Day low
2.64
Volume
408.26K
Market cap
$2.95M
P/E (TTM)
—
52W range
2.27 – 28.95
Day trading desk
Gap from prior close
+1.42%
Prior close 2.82
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
10.88%
2.85 – 3.16
Position in range
26%
Near session low
ATR (14D)
0.36
12.33% of price
Prior day high
3.00
PDH
Prior day low
2.43
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 403.17K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+4.51%
+2.6%
1M
+1,562.98%
+1,561.8%
3M
+384.70%
+380.2%
6M
+447.27%
+429.1%
YTD
+413.65%
+399.4%
1Y
+55.96%
+39.5%
3Y
-53.69%
-135.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MTNB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 10, 26 | STERN ADAM K. Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 1.07M | $400.63K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
STERN ADAM K. |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
Fundamentals
Market cap$2.95M
Enterprise value$2.19M
Revenue (TTM)—
Gross profit$0
EBITDA$-6.66M
Net income$-7.31M
EPS (TTM)$-17.55
Free cash flow$-2.45M
Total cash$761.00K
Total debt$6.00K
Book value / share$4.22
Shares outstanding979.52K
Float763.08K
Short % of float3.00%
Dividend yield0.00%
Beta (5Y)2.08
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.00
PEG ratio—
Price / sales—
Price / book0.71
EV / revenue—
EV / EBITDA-0.33
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-141.24%
Return on assets-56.17%
Debt / equity0.33
Current ratio0.85
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $1.10M | $3.19M | — |
| Operating revenue | $0 | $0 | $1.10M | $3.19M | — |
| Research & development | $85.00K | $11.43M | $14.49M | $16.68M | -99.3% |
| Selling, general & admin | $6.88M | $8.73M | $10.37M | $11.10M | -21.2% |
| Total operating expense | $6.96M | $20.16M | $24.86M | $27.78M | -65.5% |
| Operating income | -$6.96M | -$20.16M | -$23.77M | -$24.59M | +65.5% |
| Pre-tax income | -$10.35M | -$24.33M | -$22.94M | -$21.00M | +57.5% |
| Tax provision | $0 | -$80.00K | $0 | — | +100.0% |
| Net income | -$10.35M | -$24.25M | -$22.94M | -$21.00M | +57.3% |
| Net income to common | -$10.96M | -$24.25M | -$22.94M | -$21.00M | +54.8% |
| Basic EPS | -2.00 | -4.98 | -5.28 | -5.00 | +59.8% |
| Diluted EPS | -2.00 | -4.98 | -5.28 | -5.00 | +59.8% |
| EBIT | -$6.96M | -$20.16M | -$23.77M | -$24.59M | +65.5% |
| EBITDA | -$6.50M | -$19.19M | -$22.82M | -$23.69M | +66.1% |
| Basic shares | 5.47M | 4.87M | 4.35M | 4.34M | +12.5% |
| Diluted shares | 5.47M | 4.87M | 4.35M | 4.34M | +12.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $4.00M | $7.28M | $4.79M | $6.83M | -45.1% |
| Cash & short-term investments | $4.00M | $7.28M | $13.76M | $28.76M | -45.1% |
| Total current assets | $4.08M | $8.03M | $15.54M | $34.53M | -49.2% |
| Property, plant & equipment | $673.00K | $2.16M | $5.01M | $5.73M | -68.8% |
| Goodwill & intangibles | $2.26M | $2.26M | $4.35M | $4.35M | 0.0% |
| Total assets | $7.21M | $12.64M | $25.10M | $44.82M | -43.0% |
| Total current liabilities | $1.46M | $2.67M | $2.62M | $4.29M | -45.1% |
| Total debt | $1.35M | $2.89M | $3.56M | $4.12M | -53.2% |
| Total liabilities | $2.38M | $5.05M | $5.86M | $8.18M | -52.9% |
| Retained earnings | -$210.79M | -$199.82M | -$175.57M | -$152.63M | -5.5% |
| Shareholder equity | $4.83M | $7.59M | $19.25M | $36.64M | -36.4% |
| Working capital | $2.61M | $5.36M | $12.92M | $30.25M | -51.3% |
| Net tangible assets | $2.57M | $5.33M | $14.89M | $32.28M | -51.8% |
| Shares issued | 6.41M | 5.09M | 4.35M | 4.35M | +25.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$10.35M | -$24.25M | -$22.94M | -$21.00M | — | +57.3% |
| Depreciation & amortisation | $456.00K | $972.00K | $941.00K | $898.00K | — | -53.1% |
| Stock-based compensation | $1.02M | $3.19M | $4.95M | $5.23M | — | -68.0% |
| Change in working capital | -$1.51M | -$131.00K | $1.67M | -$4.79M | — | -1,052.7% |
| Operating cash flow | -$7.01M | -$15.88M | -$15.28M | -$19.16M | — | +55.9% |
| Capital expenditure | — | — | -$218.00K | -$892.00K | -$260.00K | — |
| Investing cash flow | $335.00K | $9.21M | $13.24M | $4.88M | — | -96.4% |
| Financing cash flow | $3.39M | $9.17M | -$7.00K | $79.00K | — | -63.0% |
| Free cash flow | -$7.01M | -$15.88M | -$15.50M | -$20.05M | — | +55.9% |
| End cash position | $4.25M | $7.53M | $5.04M | $7.08M | — | -43.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $0 | $0 | $0 | $0 | $0 | — | — |
| Selling, general & admin | $1.55M | $1.94M | $1.60M | $1.58M | $1.84M | — | -19.7% |
| Total operating expense | $1.55M | $1.94M | $1.60M | $1.58M | $1.84M | — | -19.7% |
| Operating income | -$1.55M | -$1.94M | -$1.60M | -$1.58M | -$1.84M | — | +19.7% |
| Pre-tax income | -$1.33M | -$1.92M | -$1.91M | -$1.53M | -$5.25M | — | +31.0% |
| Net income | -$1.33M | -$1.92M | -$1.91M | -$1.53M | -$5.25M | — | +31.0% |
| Net income to common | -$1.33M | -$1.92M | -$1.91M | -$2.15M | -$5.25M | — | +31.0% |
| Basic EPS | -0.21 | -0.30 | — | -0.40 | -1.03 | -0.33 | +30.0% |
| Diluted EPS | -0.21 | -0.30 | — | -0.40 | -1.03 | -0.33 | +30.0% |
| EBIT | -$1.55M | -$1.94M | -$1.60M | -$1.58M | -$1.84M | — | +19.7% |
| EBITDA | -$1.55M | -$1.86M | -$1.50M | -$1.25M | -$1.84M | — | +16.5% |
| Basic shares | 6.41M | 6.41M | — | 5.44M | 5.09M | 5.09M | 0.0% |
| Diluted shares | 6.41M | 6.41M | — | 5.44M | 5.09M | 5.09M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $761.00K | $2.40M | $4.00M | $5.43M | $6.53M | -68.3% |
| Cash & short-term investments | $761.00K | $2.40M | $4.00M | $5.43M | $6.53M | -68.3% |
| Total current assets | $1.14M | $2.81M | $4.08M | $5.65M | $7.27M | -59.4% |
| Property, plant & equipment | $9.00K | $599.00K | $673.00K | $1.51M | $1.63M | -98.5% |
| Goodwill & intangibles | $2.26M | $2.26M | $2.26M | $2.26M | $2.26M | 0.0% |
| Total assets | $3.41M | $5.87M | $7.21M | $9.70M | $11.42M | -41.9% |
| Total current liabilities | $1.35M | $2.13M | $1.46M | $1.50M | $1.78M | -36.5% |
| Total debt | $6.00K | $1.19M | $1.35M | $2.33M | $2.53M | -99.5% |
| Total liabilities | $1.61M | $2.85M | $2.38M | $3.23M | $3.75M | -43.5% |
| Retained earnings | -$214.03M | -$212.71M | -$210.79M | -$208.88M | -$206.72M | -0.6% |
| Shareholder equity | $1.80M | $3.02M | $4.83M | $6.46M | $7.67M | -40.4% |
| Working capital | -$207.00K | $689.00K | $2.61M | $4.16M | $5.48M | -130.0% |
| Net tangible assets | -$460.00K | $762.00K | $2.57M | $4.20M | $5.42M | -160.4% |
| Shares issued | 6.41M | 6.41M | 6.41M | 5.90M | 5.09M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$1.33M | -$1.92M | -$1.91M | -$1.53M | -$5.25M | +31.0% |
| Depreciation & amortisation | -$74.00K | $74.00K | $95.00K | $331.00K | -$98.00K | -200.0% |
| Stock-based compensation | $104.00K | $113.00K | $217.00K | $253.00K | $238.00K | -8.0% |
| Change in working capital | -$388.00K | $133.00K | -$223.00K | -$306.00K | -$481.00K | -391.7% |
| Operating cash flow | -$1.84M | -$1.60M | -$1.51M | -$1.47M | -$2.02M | -14.7% |
| Investing cash flow | $0 | $0 | $15.00K | $320.00K | $0 | — |
| Financing cash flow | -$1.00K | $0 | $58.00K | $64.00K | $1.62M | — |
| Free cash flow | -$1.84M | -$1.60M | -$1.51M | -$1.47M | -$2.02M | -14.7% |
| End cash position | $811.00K | $2.65M | $4.25M | $5.68M | $6.78M | -69.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2024 | -11.70 | -12.08 | -3.3% |
| Sep 2024 | -15.83 | -12.75 | +19.4% |
| Jun 2024 | -15.00 | -15.00 | 0.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.70
+72.25% from price
SMA 20
1.07
+180.42% from price
SMA 50
0.89
+238.06% from price
SMA 100
0.75
+288.64% from price
SMA 200
0.69
+339.10% from price
EMA 12
1.84
+59.23% from price
EMA 26
1.24
+135.48% from price
EMA 50
0.96
+205.16% from price
RSI (14)
65.5
Neutral
MACD (12,26,9)
0.60
Hist 0.29
ATR (14)
0.36
12.00% of price
Realised vol 30D
1422.2%
Annualised
Bollinger upper
3.53
20, 2σ
Bollinger lower
-1.39
20, 2σ
50 / 200 cross
Golden
0.89 vs 0.69
Trend bias
Above 200
+339.10%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
5.30
More volatile than market
Correlation to SPY
0.02
Largely independent
Realised vol 30D
1422.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-96.4%
Peak to trough
Max drawdown 5Y
-99.7%
Peak to trough
ATR 14
0.36
12.00% of price
Beta (reported)
2.08
5Y monthly, from filing
Short interest
Shares short
29.40K
Prior 14.93K
Change vs prior
+97.0%
Shorts adding
% of float
3.00%
Normal
% of shares out
3.00%
Against total outstanding
Days to cover
0.3
Liquid
Float
763.08K
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 31, 24 | Maxim Group | DOWNGRADE | Buy | Hold |
| Jan 31, 23 | HC Wainwright & Co. | MAINTAINED | — | Buy |
| Aug 13, 20 | Aegis Capital | MAINTAINED | — | Buy |
| Jan 27, 20 | Piper Sandler | INITIATED | — | Overweight |
| Jan 24, 20 | SunTrust Robinson Humphrey | INITIATED | — | Buy |
| Jun 26, 19 | HC Wainwright & Co. | INITIATED | — | Buy |
| May 17, 19 | BTIG | INITIATED | — | Buy |
| Feb 11, 19 | Roth Capital | INITIATED | — | Buy |
| Nov 13, 18 | Maxim Group | MAINTAINED | Buy | Buy |
| Aug 13, 18 | Maxim Group | MAINTAINED | Buy | Buy |
| Jul 10, 18 | Maxim Group | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:15
Split dateSep 28, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-28
Corporate Changes & Voting Matters
8-K · 2026-09-16
Corporate Changes & Voting Matters
8-K · 2026-09-04
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425 · 2026-08-25
Periodic Financial Reports
10-Q · 2026-08-13
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425 · 2026-08-04
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425 · 2026-07-30
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425 · 2026-07-29
Headlines
GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output
GlobeNewswire · 23d ago
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
GlobeNewswire · 33d ago
GH Power and TKMS Continue to Explore Clean Energy Collaboration in Support of Canada’s Future Patrol Submarine Project
Business Wire · 69d ago
GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma
Business Wire · 86d ago
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
GlobeNewswire · 86d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.